Home » Topics » BioWorld Science

BioWorld Science
RSS

Phase I trial to begin for aerosolized form of osteoporosis drug

June 14, 1996

Sanofi Winthrop launches tiludronic acid

June 14, 1996

Allergan's Acular available on U.K. market

June 14, 1996

Xalatan approved for U.S. market

June 14, 1996

Grelan to codevelop BioNumerik's BNP-7787

June 14, 1996

Betamipron offers nephrotoxicity protection

June 14, 1996

XR-9051: MDR-reversing agent

June 14, 1996

Fujisawa reveals FR-177391, agent for cachexia in cancer patients

June 14, 1996

PN 27.1 compassionate use trial broadened

June 14, 1996

Actimmune metastatic renal cell carcinoma development terminated

June 14, 1996

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...